Summary Background The Ring Study, a phase 3 trial in 1959 sexually active women
(randomised 2: 1), showed a favourable safety profile and a 31% HIV-1 infection risk …

Background Two phase 3 clinical trials showed that use of a monthly vaginal ring containing
25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by …

Background The incidence of human immunodeficiency virus (HIV) infection remains high
among women in sub-Saharan Africa. We evaluated the safety and efficacy of extended use …

Introduction A vaginal ring containing 25 mg of the antiretroviral dapivirine has
demonstrated efficacy in reducing women's risk of sexually acquiring HIV‐1; however …

Background This was the first microbicide trial conducted in Africa to evaluate an
antiretroviral-containing vaginal ring as an HIV prevention technology for women. Objectives …

Background Antiretroviral medications that are used as prophylaxis can prevent acquisition
of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among …

Background: The MTN-020/ASPIRE trial evaluated the safety and effectiveness of the
dapivirine vaginal ring for prevention of HIV-1 infection among African women. A nested …

In the continuing effort to develop effective HIV prevention methods for women, a vaginal
ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine is currently …

Objectives: Women-initiated HIV-prevention products are urgently needed. To address this
need, a trial was conducted to assess the safety and pharmacokinetics of a silicone …

Objectives: To assess the local and systemic safety of dapivirine vaginal gel vs. placebo gel
as well as the systemic absorption of dapivirine in healthy, HIV-negative women. Methods …